Intratumoral hiFLU administration also increased DCs among antigen presenting cells (APCs) in the tumor and, specifically, cross-presenting CD8+ DCs (Fig. 2 D–F and SI Appendix, Fig. S4) that have been shown to be important in antitumor and antipathogen (including oncolytic virus) immune responses (29, 30). Here, CD8A is linked to neoplasm.